SURGERY PARTNERS INC (SGRY) Stock Fundamental Analysis

NASDAQ:SGRY • US86881A1007

15.49 USD
+0.49 (+3.27%)
At close: Feb 12, 2026
15.49 USD
0 (0%)
After Hours: 2/12/2026, 8:15:43 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

SGRY gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 102 industry peers in the Health Care Providers & Services industry. There are concerns on the financial health of SGRY while its profitability can be described as average. SGRY is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • In the past year SGRY was profitable.
  • In the past year SGRY had a positive cash flow from operations.
  • In the past 5 years SGRY always reported negative net income.
  • Each year in the past 5 years SGRY had a positive operating cash flow.
SGRY Yearly Net Income VS EBIT VS OCF VS FCFSGRY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

1.2 Ratios

  • SGRY has a Return On Assets (-2.16%) which is comparable to the rest of the industry.
  • With a Return On Equity value of -9.94%, SGRY perfoms like the industry average, outperforming 44.12% of the companies in the same industry.
  • SGRY has a Return On Invested Capital (5.57%) which is in line with its industry peers.
  • SGRY had an Average Return On Invested Capital over the past 3 years of 5.03%. This is below the industry average of 9.04%.
  • The 3 year average ROIC (5.03%) for SGRY is below the current ROIC(5.57%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA -2.16%
ROE -9.94%
ROIC 5.57%
ROA(3y)-1.04%
ROA(5y)-1.46%
ROE(3y)-4.24%
ROE(5y)-9.69%
ROIC(3y)5.03%
ROIC(5y)4.49%
SGRY Yearly ROA, ROE, ROICSGRY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

1.3 Margins

  • SGRY's Operating Margin of 15.78% is amongst the best of the industry. SGRY outperforms 93.14% of its industry peers.
  • In the last couple of years the Operating Margin of SGRY has remained more or less at the same level.
  • Looking at the Gross Margin, with a value of 26.57%, SGRY is in line with its industry, outperforming 55.88% of the companies in the same industry.
  • In the last couple of years the Gross Margin of SGRY has remained more or less at the same level.
Industry RankSector Rank
OM 15.78%
PM (TTM) N/A
GM 26.57%
OM growth 3Y3.68%
OM growth 5Y1.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.83%
GM growth 5Y-0.73%
SGRY Yearly Profit, Operating, Gross MarginsSGRY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so SGRY is destroying value.
  • Compared to 1 year ago, SGRY has more shares outstanding
  • Compared to 5 years ago, SGRY has more shares outstanding
  • Compared to 1 year ago, SGRY has a worse debt to assets ratio.
SGRY Yearly Shares OutstandingSGRY Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
SGRY Yearly Total Debt VS Total AssetsSGRY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

  • SGRY has an Altman-Z score of 0.75. This is a bad value and indicates that SGRY is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of SGRY (0.75) is worse than 71.57% of its industry peers.
  • The Debt to FCF ratio of SGRY is 18.37, which is on the high side as it means it would take SGRY, 18.37 years of fcf income to pay off all of its debts.
  • SGRY's Debt to FCF ratio of 18.37 is in line compared to the rest of the industry. SGRY outperforms 41.18% of its industry peers.
  • A Debt/Equity ratio of 2.00 is on the high side and indicates that SGRY has dependencies on debt financing.
  • SGRY's Debt to Equity ratio of 2.00 is on the low side compared to the rest of the industry. SGRY is outperformed by 73.53% of its industry peers.
Industry RankSector Rank
Debt/Equity 2
Debt/FCF 18.37
Altman-Z 0.75
ROIC/WACC0.63
WACC8.79%
SGRY Yearly LT Debt VS Equity VS FCFSGRY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.3 Liquidity

  • A Current Ratio of 1.88 indicates that SGRY should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.88, SGRY is in the better half of the industry, outperforming 78.43% of the companies in the same industry.
  • SGRY has a Quick Ratio of 1.72. This is a normal value and indicates that SGRY is financially healthy and should not expect problems in meeting its short term obligations.
  • With a decent Quick ratio value of 1.72, SGRY is doing good in the industry, outperforming 72.55% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.88
Quick Ratio 1.72
SGRY Yearly Current Assets VS Current LiabilitesSGRY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • SGRY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.02%.
  • Looking at the last year, SGRY shows a quite strong growth in Revenue. The Revenue has grown by 10.14% in the last year.
  • Measured over the past years, SGRY shows a quite strong growth in Revenue. The Revenue has been growing by 11.20% on average per year.
EPS 1Y (TTM)-17.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.58%
Revenue 1Y (TTM)10.14%
Revenue growth 3Y11.86%
Revenue growth 5Y11.2%
Sales Q2Q%6.63%

3.2 Future

  • SGRY is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.89% yearly.
  • The Revenue is expected to grow by 7.88% on average over the next years.
EPS Next Y-29.92%
EPS Next 2Y-10.69%
EPS Next 3Y0.93%
EPS Next 5Y12.89%
Revenue Next Year6.88%
Revenue Next 2Y7.52%
Revenue Next 3Y7.62%
Revenue Next 5Y7.88%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SGRY Yearly Revenue VS EstimatesSGRY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1B 2B 3B 4B
SGRY Yearly EPS VS EstimatesSGRY Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 1 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 19.86, SGRY is valued on the expensive side.
  • Compared to the rest of the industry, the Price/Earnings ratio of SGRY indicates a somewhat cheap valuation: SGRY is cheaper than 75.49% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 27.67, SGRY is valued a bit cheaper.
  • With a Price/Forward Earnings ratio of 20.66, SGRY is valued on the expensive side.
  • Based on the Price/Forward Earnings ratio, SGRY is valued a bit cheaper than the industry average as 61.76% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of SGRY to the average of the S&P500 Index (27.69), we can say SGRY is valued slightly cheaper.
Industry RankSector Rank
PE 19.86
Fwd PE 20.66
SGRY Price Earnings VS Forward Price EarningsSGRY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 77.45% of the companies in the same industry are more expensive than SGRY, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, SGRY is valued cheaply inside the industry as 83.33% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 10.33
EV/EBITDA 8.23
SGRY Per share dataSGRY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 -20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.69%
EPS Next 3Y0.93%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • SGRY does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SURGERY PARTNERS INC

NASDAQ:SGRY (2/12/2026, 8:15:43 PM)

After market: 15.49 0 (0%)

15.49

+0.49 (+3.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-10
Earnings (Next)03-02
Inst Owners80.81%
Inst Owner Change1.01%
Ins Owners1.11%
Ins Owner Change0.05%
Market Cap2.00B
Revenue(TTM)3.29B
Net Income(TTM)-171.90M
Analysts81.11
Price Target25.96 (67.59%)
Short Float %20.04%
Short Ratio9.78
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.56%
Min EPS beat(2)-23.03%
Max EPS beat(2)24.15%
EPS beat(4)2
Avg EPS beat(4)-2.06%
Min EPS beat(4)-24.34%
Max EPS beat(4)24.15%
EPS beat(8)5
Avg EPS beat(8)2.45%
EPS beat(12)9
Avg EPS beat(12)185.54%
EPS beat(16)10
Avg EPS beat(16)107.47%
Revenue beat(2)0
Avg Revenue beat(2)-1.38%
Min Revenue beat(2)-1.9%
Max Revenue beat(2)-0.85%
Revenue beat(4)1
Avg Revenue beat(4)-0.63%
Min Revenue beat(4)-2.1%
Max Revenue beat(4)2.34%
Revenue beat(8)3
Avg Revenue beat(8)-0.61%
Revenue beat(12)4
Avg Revenue beat(12)-0.71%
Revenue beat(16)5
Avg Revenue beat(16)-1.03%
PT rev (1m)-2.1%
PT rev (3m)-18.41%
EPS NQ rev (1m)-5.17%
EPS NQ rev (3m)-38.62%
EPS NY rev (1m)0%
EPS NY rev (3m)-24.86%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)-6.83%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.84%
Valuation
Industry RankSector Rank
PE 19.86
Fwd PE 20.66
P/S 0.61
P/FCF 10.33
P/OCF 7.11
P/B 1.16
P/tB N/A
EV/EBITDA 8.23
EPS(TTM)0.78
EY5.04%
EPS(NY)0.75
Fwd EY4.84%
FCF(TTM)1.5
FCFY9.68%
OCF(TTM)2.18
OCFY14.07%
SpS25.42
BVpS13.37
TBVpS-26.33
PEG (NY)N/A
PEG (5Y)N/A
Graham Number15.32
Profitability
Industry RankSector Rank
ROA -2.16%
ROE -9.94%
ROCE 7.05%
ROIC 5.57%
ROICexc 5.57%
ROICexgc 18.41%
OM 15.78%
PM (TTM) N/A
GM 26.57%
FCFM 5.9%
ROA(3y)-1.04%
ROA(5y)-1.46%
ROE(3y)-4.24%
ROE(5y)-9.69%
ROIC(3y)5.03%
ROIC(5y)4.49%
ROICexc(3y)5.23%
ROICexc(5y)4.72%
ROICexgc(3y)18.5%
ROICexgc(5y)17.9%
ROCE(3y)6.37%
ROCE(5y)5.69%
ROICexgc growth 3Y0.78%
ROICexgc growth 5Y0.88%
ROICexc growth 3Y4.99%
ROICexc growth 5Y3.37%
OM growth 3Y3.68%
OM growth 5Y1.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.83%
GM growth 5Y-0.73%
F-Score4
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 2
Debt/FCF 18.37
Debt/EBITDA 5.17
Cap/Depr 58.56%
Cap/Sales 2.67%
Interest Coverage 250
Cash Conversion 42.14%
Profit Quality N/A
Current Ratio 1.88
Quick Ratio 1.72
Altman-Z 0.75
F-Score4
WACC8.79%
ROIC/WACC0.63
Cap/Depr(3y)68.21%
Cap/Depr(5y)61.64%
Cap/Sales(3y)3.1%
Cap/Sales(5y)2.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.58%
EPS Next Y-29.92%
EPS Next 2Y-10.69%
EPS Next 3Y0.93%
EPS Next 5Y12.89%
Revenue 1Y (TTM)10.14%
Revenue growth 3Y11.86%
Revenue growth 5Y11.2%
Sales Q2Q%6.63%
Revenue Next Year6.88%
Revenue Next 2Y7.52%
Revenue Next 3Y7.62%
Revenue Next 5Y7.88%
EBIT growth 1Y15.88%
EBIT growth 3Y15.97%
EBIT growth 5Y12.77%
EBIT Next Year41.53%
EBIT Next 3Y20.05%
EBIT Next 5YN/A
FCF growth 1Y32.24%
FCF growth 3Y92.28%
FCF growth 5Y30.27%
OCF growth 1Y18.25%
OCF growth 3Y51.04%
OCF growth 5Y18.3%

SURGERY PARTNERS INC / SGRY FAQ

Can you provide the ChartMill fundamental rating for SURGERY PARTNERS INC?

ChartMill assigns a fundamental rating of 3 / 10 to SGRY.


What is the valuation status for SGRY stock?

ChartMill assigns a valuation rating of 4 / 10 to SURGERY PARTNERS INC (SGRY). This can be considered as Fairly Valued.


How profitable is SURGERY PARTNERS INC (SGRY) stock?

SURGERY PARTNERS INC (SGRY) has a profitability rating of 4 / 10.


What is the financial health of SURGERY PARTNERS INC (SGRY) stock?

The financial health rating of SURGERY PARTNERS INC (SGRY) is 2 / 10.


What is the earnings growth outlook for SURGERY PARTNERS INC?

The Earnings per Share (EPS) of SURGERY PARTNERS INC (SGRY) is expected to decline by -29.92% in the next year.